CENTENNIAL, Colorado, May 17, 2019 – Cell>Point announced today that it plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the company’s new one-vial Oncardia® (ethylenedicysteine-glucosamine) kits. The 60 patient trial study is being conducted in the U.S.
Today, slightly greater than 6 million nuclear cardiology perfusion imaging scans are performed in the U.S. annually. Such procedures, referred to as myocardial perfusion imaging (MPI), are performed using either SPECT or PET camera systems. SPECT MPI procedures represent 98% of the total. All MPI procedures, regardless of the choice of radiopharmaceutical agent, are designed to illuminate the healthy perfused part of the heart. A high percentage of the patients are required to undergo a time-consuming rest and separate stress study. While there are several cardiovascular disease indicators that can be looked at with MPI, the predominant focus for such studies is the presence, location and severity of myocardial ischemia following a heart attack.
99mTc-Oncardia® is not a perfusion agent. It being clinically studied as the first functional cardiovascular imaging agent that is target specific for myocardial ischemia. One of the clinical objectives of the study is to demonstrate that 99mTc-Oncardia® can be effectively used where the patient does not need to be either physically or pharmacologically stressed for the study. If a rest only study is clinically validated, 99mTc-Oncardia® has the potential to change the dynamic for how nuclear cardiac scans are performed. 99mTc-Oncardia® is for use with SPECT camera systems. CellPoint also is planning to clinically study 68Ga-Oncardia® for use with PET camera systems.
ABOUT CELLPOINT, L.L.C.
CellPoint is a biopharmaceutical company focused on the development of universal molecular imaging compounds and molecular therapeutics for the diagnosis, staging, treatment and treatment monitoring of cancer, cardiovascular disease, and a range of ischemic diseases. CellPoint has exclusive licenses to five drug-development platforms, all from The University of Texas MD Anderson Cancer Center in Houston, a world leader in cancer research and care. Information on Cell>Point’s product candidates and licenses, recent press releases, and patents and patent filings can be obtained through its website at www.cellpointweb.com. The Company has offices in Centennial, Colorado and Houston, Texas.